Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China

By Zhongliang Wang, Bohan Yang, Qianwen Li, Lu Wen, Ruiguang Zhang. Clinical Infectious Diseases, 2020

1,044 citations recorded by the source corpus.

Abstract Background From December 2019 to February 2020, 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China. Related clinical features are needed. Methods We reviewed 69 patients who were hospitalized in Union hospital in Wuhan between January 16 to January 29, 2020. All patients were confirmed to be infected with SARS-CoV-2 and the final date of follow-up was February 4, 2020. Results The median age of 69 enrolled patients was 42.0 years (IQR 35.0-62.0), and 32 patients (46%) were men. The most common symptoms were fever (60[87%]), cough (38[55%]), and fatigue (29[42%]). Most patients received antiviral therapy (66 [98.5%] of 67 patients) and antibiotic therapy (66 [98.5%] of 67 patients). As of February 4, 2020, 18 (26.9%) of 67 patients had been discharged, and five patients had died, with a mortality rate of 7.5%. According to the lowest SpO2 during admission, cases were divided into the SpO2≥90% group (n=55) and the SpO2<90% group (n=14). All 5 deaths occurred in the SpO2<90% group. Compared with SpO2≥90% group, patients of the SpO2<90% group were older, and showed more comorbidities and higher plasma levels of IL6, IL10, lactate dehydrogenase, and c reactive protein. Arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate. Conclusions COVID-19 appears to show frequent fever, dry cough, and increase of inflammatory cytokines, and induced a mortality rate of 7.5%. Older patients or those with underlying comorbidities are at higher risk of death.

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/375ac8bd5fad1388ef3f14cce034ab83231a5907

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

T. Rawson
N. Zhu
Luke S.P. Moore
Nisha Ranganathan
K. Skolimowska
M. Gilchrist
G. Satta
G. Cooke

Citations in the corpus

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. (2020, methodology): “We read with interest the paper by Wang et al [1] describing the clinical features of 69 patients with Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infection in Wuhan, China.”
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? (2020, neutral): “Most studies suggested that elevated CRP levels were associated with severe COVID-19 [37,53,54], with a few exceptions [35].”
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease (2020, neutral): “Various authors have detected this interleukin in patients with COVID-19 and related its levels to disease severity and progression, as in the case of other cytokines [17,43,57,64,82,83,86,88,89] and it has been reported to have possible prognostic value [54].”
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (2020, neutral): “(%) ICU: 13 (32); ARDS: 12 (29); MI: 5 (12); AKI: 3 (7); shock: 3 (7); secondary infection: 4 (10) ICU: 23 (23); ARDS: 17 (17); AKI: 3 (3); shock: 4 (4); VAP: 1 (1) ICU: 36 (26); ARDS: 27 (20); MI: 10 (7.”